890839-24-4Relevant academic research and scientific papers
Development of a large scale asymmetric synthesis of vanilloid receptor (TRPV1) antagonist ABT-102
Lukin, Kirill,Hsu, Margaret C.,Chambournier, Gilles,Kotecki, Brian,Venkatramani,Leanna
, p. 578 - 584 (2007)
A highly efficient asymmetric synthesis of TRPV1 antagonist ABT-102 was developed and successfully demonstrated on a multi-kilogram scale. This process incorporates a new asymmetric synthesis of (R)-tert-butylaminoindan, which is based on a chiral auxiliary induced diastereoselective reduction of its iminoindan precursor.
Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof
-
Page/Page column 12, (2008/06/13)
The present invention is directed to compounds of formula (I) wherein variables X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3, and A4 are as defined
Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
-
Page/Page column 18, (2008/06/13)
Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
